Literature DB >> 8457709

In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).

A A el-Zayat1, D Degen, S Drabek, G M Clark, G R Pettit, D D Von Hoff.   

Abstract

Combretastatin A-4 is a natural product which was isolated from the South African tree Combretum caffrum. In this study, the cytotoxic activity of combretastatin A-4 was tested in radiometric and human tumor cloning assays against eight different tumor cell lines and against 15 patient tumors in the human tumor cloning assay. To test the preferential cytotoxicity of combretastatin A-4 against tumor cells versus non-tumor cells, it was also tested in the radiometric assay against both normal human diploid fibroblasts and human bone marrow cells. Of the eight cell lines used, combretastatin A-4 showed preferential cytotoxicity for six of them. In addition, combretastatin A-4 showed a concentration-dependent cytotoxicity against a variety of human tumors. Based on the data generated in this study, combretastatin A-4 should be further tested in in vivo preclinical models.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8457709     DOI: 10.1097/00001813-199302000-00002

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  11 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).

Authors:  Matthew T Macdonough; Tracy E Strecker; Ernest Hamel; John J Hall; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2013-07-23       Impact factor: 3.641

3.  Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.

Authors:  Carsten D Ley; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

4.  Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor.

Authors:  R T Dorr; K Dvorakova; K Snead; D S Alberts; S E Salmon; G R Pettit
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

Authors:  G J Rustin; G Shreeves; P D Nathan; A Gaya; T S Ganesan; D Wang; J Boxall; L Poupard; D J Chaplin; M R L Stratford; J Balkissoon; M Zweifel
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

6.  Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.

Authors:  Vinod Kumar Sanna; Manu Jaggi; Vadlapudi Kumar; Anand C Burman
Journal:  Invest New Drugs       Date:  2009-05-08       Impact factor: 3.850

7.  A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.

Authors:  Colin J Mooney; Govardhanan Nagaiah; Pingfu Fu; Jay K Wasman; Matthew M Cooney; Panos S Savvides; Joseph A Bokar; Afshin Dowlati; Ding Wang; Sanjiv S Agarwala; Susan M Flick; Paul H Hartman; Jose D Ortiz; Pierre N Lavertu; Scot C Remick
Journal:  Thyroid       Date:  2009-03       Impact factor: 6.568

Review 8.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

9.  Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.

Authors:  Astrid Bernhaus; Maria Ozsvar-Kozma; Philipp Saiko; Margit Jaschke; Andreas Lackner; Michael Grusch; Zsuzsanna Horvath; Sibylle Madlener; Georg Krupitza; Norbert Handler; Thomas Erker; Walter Jaeger; Monika Fritzer-Szekeres; Thomas Szekeres
Journal:  Invest New Drugs       Date:  2008-10-08       Impact factor: 3.850

10.  Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.

Authors:  Mengen Zhang; Rui Guo; Yin Wang; Xueyan Cao; Mingwu Shen; Xiangyang Shi
Journal:  Int J Nanomedicine       Date:  2011-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.